Elsevier

Peptides

Volume 34, Issue 2, April 2012, Pages 353-359
Peptides

Cortistatin modulates the expression and release of corticotrophin releasing hormone in rat brain. Comparison with somatostatin and octreotide

https://doi.org/10.1016/j.peptides.2012.02.004Get rights and content

Abstract

Cortistatin (CST) is an endogenous neuropeptide characterized by remarkable structural and functional resemblance to somatostatin (SST), both peptides sharing the ability to bind and activate all five SST receptor subtypes. Evidence is also available showing that CST exerts biological activities independently from SST, perhaps via the activation of specific receptors that remain to be fully characterized at present. Here we have investigated the effects of CST on the gene expression and release of corticotrophin releasing hormone (CRH) from rat hypothalamic and hippocampal explants; moreover, we compared the effects of CST with those of SST and octreotide (OCT) in these models. We found that: (i) CST inhibits the expression and release of CRH from rat hypothalamic and hippocampal explants under basal conditions as well as after CRH stimulation by well known secretagogues; (ii) SST does not modify basal CRH secretion from the hypothalamus or the hippocampus, while it is able to reduce KCl-stimulated CRH release from both brain areas; (iii) OCT inhibits both basal and KCl-induced CRH secretion from rat hypothalamic explants, while it has no effect on CRH release from the hippocampus, either under basal conditions or after stimulation by high K+ concentrations; (iv) at variance with CST; SST and OCT have not effect whatsoever on veratridine-induced CRH release from the hypothalamus. In conclusion the present findings provide in vitro evidence in support of the hypothesis that CST plays a role in the regulation of endocrine adaptive responses to stress.

Highlights

► We investigated the effects of cortistatin on CRH production from isolated rat brain regions. ► We also compared the action of cortistatin with those of somatostatin and octreotide. ► Cortistatin inhibited the release and gene expression of CRH from rat hypothalamus. ► Cortistatin inhibited basal and stimulated CRH release from rat hippocampus. ► Somatostatin and octreotide showed a different action profile from cortistatin.

Introduction

Cortistatin (CST) is a 14-aa neuropeptide belonging to the family of somatostatin (SST)-like Cys–Cys loop peptides; it was cloned from human, rat and mouse tissues [38]. In the rat, CST is synthesized as a prepropeptide (preproCST) yielding two biologically active peptides: CST-29 and CST-14 (thereafter referred to as CST), the latter preferentially released via the regulated secretory pathway [18], [34]. CST possesses a remarkable structural similarity to SST-14, although it is the product of a different gene [16], [17]. In fact, CST shares 11 out of 14 amino acids with SST-14, including the amino acid sequence phe-trp-lys-thr required to bind all five cloned SST receptors (SST-R1–SST-R5) [48]. These analogies explain certain common biological activities of CST and SST, including the depression of neuronal activity, the inhibition of cell proliferation and endocrine and metabolic activities [6], [9], [16], [22]. However, the profile of CST is not simply redundant with respect to SST; in fact, several studies showed marked differences between the two hormones in terms of tissues distribution, regulation of synthesis and biological actions, especially in the central nervous system (CNS) and immune system [5], [8], [20], [23], [27]. Based on these differences, specific CST receptors, able to bind selectively CST but not SST, have been postulated. Putative CST receptors are the Mas-related gene X2 (MrgX2) receptor and the GHS-R1a ghrelin receptor [1], [15], [35]. MrgX2 receptor is not expressed in the cerebral cortex, where CST expression is most abundant [35]; MrgX2 appears to be non-specific to CST, since it acts as a receptor for pro-adrenomedullin and related peptides [31] as well. The possible role GHS-R1a as CST receptor has also been questioned. Therefore, the existence of specific CST receptors remains under scrutiny. On this regard, truncated but functional SST5 receptor variants have recently been described in human, rodents and pig; these variants show distinct ligand-selective signaling profiles with respect to CST and SST, respectively [12], [13].

Corticotrophin-releasing hormone (CRH) is a 41-amino acid neuropeptide originally isolated from the ovine hypothalamus [46]. The CRH system currently includes two receptors sub-families (CRH-R1 and -R2), and four ligands (CRH and the related peptides Urocortin I, II, and III) as well a CRH-binding protein [2]. CRH plays a major role in coordinating the behavioral, endocrine, autonomic and immune responses to stress. In fact, CRH produced in the paraventricular nucleus in response to stress modulates ACTH release from the anterior pituitary via CRH-R1 [47], with consequent increases in glucocorticoid secretion from the adrenal cortex. Basal glucocorticoid levels and transient increases during stress are essential for neuronal plasticity and normal brain function. On the contrary, chronic stress causes inappropriate CRH and glucocorticoid levels, with consequent metabolic and immune changes. Extra-hypothalamic CRH seems to play a important role in behavioral adaptive responses to stress as well as in the development of affective disorders [2], [4]. In fact, CRH and its receptors are widely distributed throughout the brain. In particular, the hippocampus displays the highest concentrations of CRH-binding sites and CRH-immunoreactive nerve terminals [10], [19], suggesting that CRH might modulate important hippocampal functions, associated to the control of emotions and response to stress. Indeed, CRH was shown to be secreted directly from nerve terminals within the hippocampus during exposure to stress [10]. A large body of evidence shows that an altered functioning of CRH system may be critical in the development of affective disorders, including anxiety, depression and stress-related disorders [3], [29]. On this line of evidence, it was suggested that the efficacy of anti-depressive agents is associated to the reduction of CRH production and release within the CNS [24]. In this regard, our group showed that different drugs used in mood disorders share the ability to reduce, through different mechanisms, the production and release of CRH from rat hypothalamic and hippocampal explants [21], [42], [44], [45].

The possible role of SST in the control of stress responses has been investigated in the last decades, showing that SST might blunt stress responses both via a direct inhibitory action on hypothalamic CRH [41] and the inhibition of CRH-stimulated ACTH release at pituitary level [39]. Instead, the putative effects of CST in stress control have received so far little attention. Within this framework, in the present study we investigated the effects of CST on the release of CRH from two rat brain areas, namely the hypothalamus and the hippocampus. Moreover, we compared the effects of CST with those of SST and its stable analog Octreotide (OCT) in the same paradigm.

Section snippets

Animals

Male Wistar rats (200–300 g) were used. They were kept four per cage and maintained at a temperature of 23 ± 1.5 °C, with a relative humidity of 65 ± 2%. The animals were exposed to 12-h light (06.00–18.00 h) followed by 12-h dark, and had free access to food and water. The use of animals for this experimental work has been approved by the Italian Ministry of Health (licensed authorization to P. Navarra).

Hypothalamic and hippocampal incubations

On day of the experiment the animals were decapitated between 09.00 and 10.00 a.m. and the brains

Effects of CST, SST and OCT on basal CRH release from rat hypothalamic explants

The first series of experiments was carried out on rat hypothalamic explants; the latter release measurable amounts of CRH under basal and stimulated conditions [45]. In 1 h incubation experiments, CST induced a reduction in CRH release that was statistically significant at 1 μM (Fig. 1A). In the same experimental paradigm, SST given in the range 10–1000 nM showed a trend toward inhibition of basal CRH release which it was not statistically significant (Fig. 1B). On the contrary, OCT, a

Discussion

In the present study we show for the first time that CST negatively modulates the expression and release of CRH from rat hypothalamic and hippocampal explants; these in vitro actions suggest that CST might have a role in the regulation of adaptive responses to stress.

Several studies showed that CST possesses the same actions of SST in different endocrine systems in vivo but especially in vitro, so that some researchers consider CST as a natural duplicate to SST with regard to its endocrine

References (49)

  • M.B. Müller et al.

    Getting closer to affective disorders: the role of CRH receptor systems

    Trends Mol Med

    (2004)
  • H.P. Nothacker et al.

    Proadrenomedullin N-terminal peptide and cortistatin activation of MrgX2 receptor is based on a common structural motif

    Eur J Pharmacol

    (2005)
  • Y.C. Patel et al.

    The somatostatin receptor family

    Life Sci

    (1995)
  • Y.C. Patel

    Somatostatin and its receptor family

    Front Neuroendocrinol

    (1999)
  • N. Robas et al.

    MrgX2 is a high potency cortistatin receptor expressed in dorsal root ganglion

    J Biol Chem

    (2003)
  • E. Saus et al.

    Comprehensive copy number variant (CNV) analysis of neuronal pathways genes in psychiatric disorders identifies rare variants within patients

    J Psychiatr Res

    (2010)
  • S. Schulz et al.

    Localization of five somatostatin receptors in the rat central nervous system using subtype-specific antibodies

    J Physiol

    (2000)
  • A.D. Spier et al.

    Cortistatin: a member of the somatostatin neuropeptide family with distinct physiological functions

    Brain Res Brain Res Rev

    (2000)
  • G. Tringali et al.

    Interleukin-18 displays effects opposite to those of interleukin-1 in the regulation of neuroendocrine stress axis

    J Neuroimmunol

    (2005)
  • G. Tringali et al.

    Effects of olanzapine and quetiapine on corticotropin-releasing hormone release in the rat brain

    Prog Neuropsychopharmacol Biol Psychiatry

    (2009)
  • W. Vale et al.

    Chemical and biological characterization of corticotropin releasing factor

    Recent Prog Horm Res

    (1983)
  • E. Allia et al.

    Expression of cortistatin and MrgX2: a specific cortistatin receptor, in human neuroendocrine tissues and related tumours

    J Pathol

    (2005)
  • T.L. Bale et al.

    CRF and CRF receptors: role in stress responsivity and other behaviors

    Annu Rev Pharmacol Toxicol

    (2004)
  • R.H. Belmaker et al.

    Major depressive disorder

    N Engl J Med

    (2008)
  • Cited by (18)

    • Adolescent binge-like alcohol exposure dysregulates NPY and CGRP in rats: Behavioural and immunochemical evidence

      2023, Progress in Neuro-Psychopharmacology and Biological Psychiatry
      Citation Excerpt :

      Scaling up at a circuit level, Towner and colleagues have recently shown that social impairment induced by alcohol binge-like exposure in adolescent rats is negatively correlated to the activation of “social brain” regions, including prelimbic and infralimbic medial prefrontal cortex (mPFC), NAc, shell and core, central and basolateral amygdala (AMY), and anterior hypothalamus (HYP) (Towner et al., 2022). When it comes to circuit-driven behavioural modifications, more than classic neurotransmitters neuropeptides persistently shape long-lasting neuron-to-neuron communication and affectiveresponses, due to their unique characteristics - i.e. high receptor binding affinity, diffusion over relatively long distances and extended extracellular half-life compared with classical neurotransmitters (Merighi et al., 2011; Tringali et al., 2012; Brancato and Cannizzaro, 2018). Assessing alcohol-related consequences, a growing interest is focused on the contribution of the intersecting and antithetical systems of calcitonin gene-related peptide (CGRP) and neuropeptide Y (NPY), which modulate behaviour across the nuanced affective spectrum.

    • LXR activation increases the expression of GnRH AND αMSH in the rat hypothalamus in vivo

      2018, Neuroscience Letters
      Citation Excerpt :

      Hypothalami were separated by transverse section to increase exposure to metabolites treatments. The tissues were then cultured in a six-well culture dish containing 1 mL of DMEM, 1% FBS, 10 μg/mL streptomycin and glutamine pH 7,4 at 37 °C/5% CO2 [8,13], with the addition of T0901317 (10 μM) or GW3965 (10 μM) for 2, 4, 6 and 8 h. Control hemisections were incubated with vehicle for the same times. When incubation time was finished the explants were quickly frozen on dry ice and stored at −80 °C.

    • Cortistatin: A new link between the growth hormone/prolactin axis, stress, and metabolism

      2017, Growth Hormone and IGF Research
      Citation Excerpt :

      It is conceivable that augmented ACTH and corticosterone levels would lead to an increased level of anxiety, and in fact, Cort −/− mice show a chronic state of anxiety, as evaluated by behavioral tests [35]. These in vivo findings are further supported by the effect that cortistatin can exert on the main regulator of ACTH release in corticotropes, corticotropin-releasing hormone (CRH), since in rat hypothalamic and hippocampal explants, cortistatin treatment decreased CRH basal release after 1 h, and CRH mRNA expression after 3 h, while somatostatin was unable to affect its release [39]. Cortistatin not only alters the endocrine system, but also its related metabolic components, including glucose homeostasis and control of food intake and diet.

    • Regulation of the expression of LXR in rat hypothalamic and hippocampal explants

      2017, Neuroscience Letters
      Citation Excerpt :

      The hypothalami were cut longitudinally by the rostral-caudal medline, and both halves were placed in the same well [10]. The tissues were cultured in a six-well culture dish containing 1 ml of DMEM, 1% FBS, 10 μg/ml streptomycin and glutamine pH 7,4 at 37 °C/5% CO2 [10], with the addition of different concentrations of glucose (5.5, 8.5, 15.5, 25.5 mM), insulin (2.5, 5, 10 nM), cholesterol (0.7, 1.6 mM), cholic acid (10, 50 μM) for 2, 4 and 6 h. Medium for control hemisections was diluted with vehicle. When incubation time was finished the explants were quickly frozen on dry ice and stored at −80 °C.

    View all citing articles on Scopus
    View full text